Journal article
Genetic engineering approaches to improve post-translational modification of biopharmaceuticals in different production platforms
CHO Cell Line Engineering and Design, Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark1
Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark2
Austrian Centre of Industrial Biotechnology GmbH3
University of Natural Resources and Life Sciences, Vienna4
Section for Synthetic Biology, Department of Biotechnology and Biomedicine, Technical University of Denmark5
Network Engineering of Eukaryotic Cell factories, Section for Synthetic Biology, Department of Biotechnology and Biomedicine, Technical University of Denmark6
Department of Biotechnology and Biomedicine, Technical University of Denmark7
The number of approved biopharmaceuticals, where product quality attributes remain of major importance, is increasing steadily. Within the available variety of expression hosts, the production of biopharmaceuticals faces diverse limitations with respect to post-translational modifications (PTM), while different biopharmaceuticals demand different forms and specifications of PTMs for proper functionality.
With the growing toolbox of genetic engineering technologies, it is now possible to address general as well as host- or biopharmaceutical-specific product quality obstacles. In this review we present diverse expression systems derived from mammalians, bacteria, yeast, plants, and insects as well as available genetic engineering tools.
We focus on genes for knockout / knockdown and overexpression for meaningful approaches to improve biopharmaceutical PTMs and discuss their applicability as well as future trends in the field. This article is protected by copyright. All rights reserved.
Language: | English |
---|---|
Year: | 2019 |
Pages: | 2778-2796 |
ISSN: | 10970290 and 00063592 |
Types: | Journal article |
DOI: | 10.1002/bit.27101 |
ORCIDs: | Amann, Thomas , Kildegaard, Helene Faustrup , Andersen, Mikael Rørdam , 0000-0002-6104-7342 and 0000-0001-6324-9338 |